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Inappropriate T cell responses in the central nervous system (CNS) affect the pathogenesis of a broad range of
neuroinflammatory and neurodegenerative disorders that include, but are not limited to, multiple sclerosis,
amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. On the one hand immune responses can
exacerbate neurotoxic responses; while on the other hand, they can lead to neuroprotective outcomes. The
temporal and spatial mechanisms by which these immune responses occur and are regulated in the setting of
active disease have gained significant recent attention. Spatially, immune responses that affect neurodegeneration
may occur within or outside the CNS. Migration of antigen-specific CD4+ T cells from the periphery to the CNS and
consequent immune cell interactions with resident glial cells affect neuroinflammation and neuronal survival. The
destructive or protective mechanisms of these interactions are linked to the relative numerical and functional
dominance of effector or regulatory T cells. Temporally, immune responses at disease onset or during progression
may exhibit a differential balance of immune responses in the periphery and within the CNS. Immune responses
with predominate T cell subtypes may differentially manifest migratory, regulatory and effector functions when
triggered by endogenous misfolded and aggregated proteins and cell-specific stimuli. The final result is altered glial
and neuronal behaviors that influence the disease course. Thus, discovery of neurodestructive and neuroprotective
immune mechanisms will permit potential new therapeutic pathways that affect neuronal survival and slow disease
progression.
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NeuroinflammationIntroduction
The pathobiology of neurodegenerative disorders has
proven complex and multi-faceted. One commonality
between the disorders is the involvement of innate and
adaptive immune responses in the central nervous sys-
tem (CNS) [1]. The interplay between peripheral and
resident CNS immunity can affect neuroinflammatory
responses and exacerbate neurodegeneration [2]. Pre-
viously, the CNS was believed to be immune privileged
and deprived of infiltration of peripheral immune cells
[3,4]. This has since been disproven on several grounds
[4,5]. First, the CNS is composed of a unique blood* Correspondence: rlmosley@unmc.edu
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unless otherwise stated.brain barrier (BBB) that affords limits and control over
the infiltration of peripheral immune cells [4]. Control
of immune cell infiltration into the CNS is regulated
through unique cell adhesion molecules (CAMs) and
CAM ligands on BBB endothelial cells. Second, during
neuroinflammatory responses, the expression of these
CAMs can be upregulated, allowing a greater number of
adaptive immune cells to cross the BBB and interact
with resident immune cells in the brain [6-11]. Third,
T cells, such as regulatory T cells, can elicit a neuro-
protective response, thus complete ablation of T cell
infiltration to the CNS could be detrimental to the host
[12-14]. Therapies that competitively interact with CAMs
and CAM ligands can modulate the extravasation of
peripheral immune cells into the CNS. Those pharma-
ceutical agents that more selectively inhibit migration of
pro-inflammatory or deleterious T cells, but allow anti-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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beneficial and neuroprotective responses. To these ends,
the current review article aims to describe the role of
immune cells in neurodegenerative disorders, migration
of these immune cells from the periphery into the CNS,
the interactions between innate and adaptive immune re-
sponses, and pharmacologic immune modulators in neu-
roprotection. Lastly, primary data will be discussed that
support findings linking the migration of specific T cell
subsets in a disease-relevant model.
T cells and adaptive immunity
T cells represent one arm of the adaptive immune system
which is responsible for mounting a response against
foreign antigen. T cells are derived from bone marrow
lymphocyte progenitors that mature and are educated
within the thymus; whence they migrate to the periphery
and reside throughout the tissues of the body, but mainly
in spleen, lymph nodes, and peripheral circulation. T cells,
acting as effector cells, provide the impetus and signals for
directing the cellular and antibody responses necessary to
clear foreign pathogens and antigens, but also, as regula-
tory T cells (Tregs), endow immunological tolerance to
the individual and actively restrains one’s immune system
from recognizing itself as foreign.
Adaptive immunity
Both innate and adaptive immune responses are impor-
tant for mounting the body’s defense against a pathogen
or foreign microorganism. The innate response is the
first line of defense, which is relatively rapid, recognizes
a broad spectrum of antigen patterns, does not require
immune memory, and is characterized by phagocytic
activity mediated by resident mononuclear phagocytes
such as macrophages, dendritic cells, and microglia. The
adaptive immune response requires substantially greater
time to develop, produce and utilize immunological
memory, and affords narrow specificity for antigens
based on lymphoid receptors for antigen expressed by
T cells [T cell receptors (TCRs)] and B cells [immunoglob-
ulins (Igs)]. The main function of the adaptive immune
system is to recognize foreign invaders, destroy foreign
microorganisms or pathogens, and relieve pathogen-
associated toxicities. However, to initially mount an im-
mune response, the innate arm of the immune system
must first be activated by recognition via broadly-specific
pattern recognition receptors (PRRs) which recognize
microorganism-associated molecular patterns (MAMPs)
or damage-associated molecular patterns (DAMPs). In
an innate response, antigens recognized by PRRs of
mononuclear phagocytes are engulfed, digested, and pro-
cessed to bind with molecules of the major histocompati-
bility complex (MHC). Upon maturation, mononuclear
phagocytes acquire an antigen presenting capabilitywhereby processed and MHC-bound antigen is expressed
on the cell surface in a configuration necessary for T cells
to recognize the antigen via the TCR. Unlike Igs which
recognize cellular- or non-cellular-bound antigen, the
TCR only recognizes antigen presented by MHC mole-
cules on antigen presenting cells (APCs). APCs also ex-
press co-stimulatory molecules such as CD80, CD86,
CD70, CD40, and CD200 that are necessary to generate
an effective, robust, and specific immune response. As
APCs, these mononuclear phagocytes bridge the innate
and adaptive arms of the immune system by providing the
antigen and co-stimulation necessary for naïve T cells to
become activated. Additionally, APCs also deliver cytokine
signals, such as IL-12, IL-4, IL-6, and TGF-β that direct
naïve T cells to follow a program of polarized differen-
tiation and transforms them into activated T cells with
specific effector functions (see below, T cell subsets). Once
activated, T cells proliferate and undergo clonal expansion
to increase their cell number and potential to challenge
invading pathogens. One mechanism by which effector
T cells expand in the presence of antigen is to secrete pro-
growth cytokines to the surrounding environment. For in-
stance, activated T cells produce and secrete IL-2 cytokine
that binds their own IL-2R to enhance proliferation in
an autocrine fashion, as well as enhance proliferation
of surrounding T cells in a paracrine fashion [15]. In
addition, to achieve as efficient effector function as pos-
sible, activated T cells migrate to areas of infection and
inflammation to interact with other immune cells, such as
macrophages or microglia, and bestow collaborative ef-
fector functions to rid the host of a foreign assault. Thus,
T cells are important for the general cellular-mediated
response of the adaptive immune arm.
T cell subsets
T cells are generally characterized by expression of the
TCR-CD3 complex on the cell surface. While the TCR
recognizes presented antigen, it does not possess the
cytosolic machinery necessary for successful signal trans-
duction; however, the CD3 complex serves as the signa-
ling mechanism that bridges the antigen recognition and
conveyance of signal for effector function. T cells are
subdivided into two major lineages based on the expres-
sion of either CD4 or CD8 on the cell surface. CD4+
T cells are considered helper T (Th) cells. With the TCR
recognizing the antigen, the CD4 molecule acts as a co-
receptor and binds the MHC II molecule that presents
the antigen from the APC. Depending on the cytokines
generated by the APC, activated CD4+ T cells develop
into specific effector T cell (Teff ) subsets that include
type-1, −2, −17 or −9 Th cells designated as Th1, Th2,
Th17, or Th9 cells, respectively, as well as Tregs. Th
subsets secrete a variety of cytokines that act as either
pro- or anti-inflammatory mediators. Classically, Th1
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against intracellular pathogens and are characterized by
secretion of predominately IFN-γ, TNF-α, and IL-2
[16,17]. IFN-γ from Th1 cells enhances macrophage ac-
tivation necessary for immunity to pathogens that cause
listeriosis, tuberculosis, salmonellosis, and leishmaniasis.
In addition, Th1 cells produce IL-2 and IL-21 that
promote and maintain antigen-specific CD8+ cytotoxic
T lymphocytes (CTLs) that lyse virus-infected cells.
CTLs are primarily responsible for ridding the host of
intracellular pathogens and virus-infected cells. CTLs
recognize antigen presented by MHC class I, which is
expressed by most cells in the body. When activated and
expanded, CTL effectors produce perforins and gran-
zymes to induce cell-mediated cytolysis [18]. On the
other hand, Th2 cells preferentially generate help for
antibody-mediated responses, mainly through the secre-
tion of IL-4, IL-10, IL-13, and IL-5, which act on B cells
for antibody production. Because the prototypical cyto-
kines from Th1 and Th2 cells regulate the expression of
each other’s master-controlling transcription factors, this
preferentially selects T cells to differentiate into either
Th1 or Th2 effector cell types in response to pathogens
[16]. Th17 cells are a more recently discovered subset of
Teffs. They predominantly secrete IL-17, as well as
TNF-α, and are thought to be important for protection
against extracellular infections, and as such, yield a par-
ticularly heavy armament as a destructive Teff type due
primarily to the pro-inflammatory milieu secreted in
response to extracellular pathogens [19]. In addition to
the Th17 effectors, another subset expresses IL-9 and is
thought also to be important in resolution of extracel-
lular infections. The Th9 subset has been implicated in
promoting the migration of Th17 cells to the CNS [20]
and potentiation of Th17 effectors via the ability to in-
crease Th17-produced IL-17. Moreover, recent evidence
indicates that other T cell types such as Tregs, Th1, and
Th17 also can secrete IL-9 with pleiotropic effects that
may ultimately alter the predominant proinflammatory
response [21]. Th22 cells are a separate lineage of CD4+
Teffs that primarily secrete proinflammatory cytokines
such as IL-22, IL-13 and TNF-α, and express the skin
homing-associated chemokine receptors CCR4, CCR6
and CCR10 [22]. Th22 cells differentiate from naïve T
cells in the presence of IL-6 and TNF-α under control of
the transcription factors aryl hydrocarbon receptor and
GATA3. These Teffs are recruited to the skin and
thought to be involved in microbial immunity and tissue
repair and remodeling. Skin disorders such as psoriasis,
eczema, and contact dermatitis may be due to dysre-
gulation of Th22 migration or function. Each of these T
cell subsets plays crucial, yet independent roles in
mounting a robust and effective adaptive immune re-
sponse. As these effector cells provide potent weaponstoward immunity to foreign invaders, they also serve
equally as potential liabilities due to increased pro-
inflammatory cytokines, antibody-mediated cytotoxicity
to cells, or hyperactivation of innate immune cells. Thus,
regulation of the Teffs is necessary to prevent untoward
pathological sequelae.
CD4+CD25+ Tregs provide that regulation, ostensibly
via expression and control of a master regulatory tran-
scription factor, forkhead box 3 (FoxP3). Tregs are a
subset of T cells that regulate and suppress the activities
of Teffs and myeloid lineage cells such as dendritic cells,
microglia, and macrophages that comprise innate im-
munity. Tregs can be further subdivided into natural
Tregs (nTregs) that are derived from the thymus and in-
duced Tregs (iTregs) that arise from naïve T cells in the
periphery [23]. Moreover, a primary function of Tregs is
the maintenance of immunological tolerance to self and
thus, inhibition of initial auto-immune responses and
suppression of auto-reactive T cells that may arise in the
peripheral tissues. Individuals that do not produce func-
tional nTregs due to mutated FOXP3, develop immuno-
dysregulation polyendocrinopathy enteropathy X-linked
(IPEX) syndrome, a systemic, multi-organ autoimmune
disorder [24]. Treg-mediated regulatory functions are
achieved at many levels. First, Tregs inhibit initiation of
immune responses by diminishing antigen processing
and antigen presentation by MHC molecules as well as
regulating 2nd and 3rd signals from APCs. Second,
Tregs secrete anti-inflammatory cytokines such as IL-10,
IL-35, and TGF-β that suppress activated mononuclear
phagocytes and Teffs. Unlike the Th2 subset, which also
elicits anti-inflammatory and protective effects, Tregs do
not traditionally interact with B cells to elicit a response.
T cells in neurodegenerative disorders
The interplay between the innate and adaptive arms of the
immune system is essential to the relationship between
neuroinflammation, neuroprotection, and neurodegene-
ration. While neuroinflammation and neurodegeneration
are associated with the pathobiology of neurodegenerative
diseases, they are also responsible for the overall neuro-
protective homeostasis of the host CNS in infectious or
neoplastic disease surveillance. Similarities between mul-
tiple neurological disorders have provided common me-
chanisms of immune interactions that lead to protective
or destructive effects within the CNS and peripheral
nervous system (PNS). Although neuroinflammation and
T cell interactions play a prominent role in disease pro-
gression, it should be noted that the immune response
can vary from a very prominent primary T cell response,
as in multiple sclerosis (MS), to seemingly less intense,
though present, T cell response as in the cases of amyo-
trophic lateral sclerosis (ALS), Alzheimer’s disease (AD)
and Parkinson’s disease (PD). However, it should also be
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are observed in these neurodegenerative diseases, particu-
larly in AD, PD and ALS, thus this commonality warrants
further elaboration. Recent findings in human neurode-
generative disorders and in corresponding animal models
have shown the involvement and putative mechanisms of
T cells and subsequent secondary responses in disease
initiation and progression.
Multiple sclerosis
MS is a chronic, progressive demyelinating inflammatory
disorder that is principally driven by T cells specific for
self-antigens expressed in the myelin sheath [25,26]. This
notion is supported largely by data showing the presence
of activated myelin-reactive T cells as well as CD4+
T cell infiltrates in MS patients affect the disease course
[27-29]. As such, therapeutic modalities and clinical trial
strategies have primarily targeted components of the
immune system. While no modality has proven to be
curative, and clinical trial outcomes varied extensively
with little to no efficacy, some with beneficial effect,
and others with devastating side effects, results have
furthered our understanding on the pathogenesis of
MS [30].
Evidence supports activated CD4+ myelin-reactive
T cells as a driving force behind MS [29]. However, a
compounding complexity of the disease arises from the
finding that both healthy controls and MS patients have
similar numbers of circulating T cells reactive to compo-
nents of myelin [29]. Thus, the mere presence of self-
reactive T cells is not sufficient evidence to explain the
development of MS. Prior to the discovery of Th17 cells,
MS was considered a purely Th1-mediated disease.
However, recent studies lead to the view that MS is nei-
ther a purely Th1- nor Th17-mediated disease. As with
EAE, both Teff subtypes are thought to participate in the
pathology of MS, but with relative dominance of each
Teff type playing a critical role in the progression of MS,
affecting the temporal course and clinical variants [27].
For instance, T cells stained for expression of IL-17 are
reported to be higher in early active plaques compared
with chronic active or inactive plaques [31]. Similar
ex vivo data showed that peripheral blood mononuclear
cells (PBMCs) derived from MS patients taken within
2 years of diagnosis produced higher levels of IL-17 in vitro
compared with those taken from patients with long-
standing disease [32].
The frequencies of Tregs in both the blood and cere-
bral spinal fluid (CSF) of MS patients have been exten-
sively investigated [33-36]. Interestingly, when brain
tissue was examined from 16 untreated MS patients, no
Tregs were found in 30% of the biopsies, and the num-
ber of FoxP3+ cells was generally low in the brain tissue
[37] suggesting Tregs may not be capable of infiltratingthe CNS in MS patients, and therefore, immune re-
sponses are un-regulated. While further studies showed
no significant differences in the number of Tregs from
the peripheral blood or CSF of MS patients compared
to healthy controls, the functional capabilities of Tregs
were impaired in patients suffering from MS [38].
The functional impairment of Tregs from MS patients
could not be attributed to a higher activation status of
Teffs, but rather seemed intrinsic to the Tregs themselves
[38]. Indeed, experiments examining Treg functionality
led by separate investigators found MS patients had lower
mRNA and protein expression levels of the Treg tran-
scription factor, FOXP3, when compared to healthy con-
trols [38-40]. Venken et al. made similar findings in
patients suffering from relapsing-remitting MS. However,
FOXP3 expression and Treg functionality was normal
during secondary progressive MS [40]. Whether Treg
dysfunction in MS represents a general defect in the
regulatory network of the immune system, and as such is
a causative factor, remains to be elucidated [38].
Experimental autoimmune encephalomyelitis (EAE) has
been the primary model of CNS autoimmune disease for
over half a century [41]. The use of EAE has expanded the
understanding of immune regulation of autoimmune dis-
ease. Furthermore, the EAE model affords evidence rea-
ching beyond MS, providing mechanisms by which Teffs
gain entry into the brain [6]. In adoptive transfer studies
of EAE, researchers have shown that myelin-reactive
T cells polarized to either a Th1 or Th17 phenotype are
capable of initiating disease in recipient mice, but the
histopathological outcome from the two T cell populations
were distinct. In animals that received Th1 polarized cells,
macrophages were more prominent, whereas Th17 recipi-
ent mice showed a more severe neutrophil infiltration
[42]. This suggested that while both Th1 and Th17 cells
play a role in de-myelination and disease progression,
their mechanisms of destruction may be different. In
addition to demonstrating different subsets of Teffs that
elicit different pathological signs in EAE, studies also
showed a temporal involvement of Th1 and Th17 in dis-
ease progression. Results demonstrated an early involve-
ment of Th17 cells, with Th1 cells becoming predominant
prior to disease resolution. Dardalhon and colleagues
proposed this shift in polarization might be related to the
natural course and recovery from an attack of EAE [43].
To address the role of CD25+ T cells in autoimmunity,
Sakaguchi and colleagues demonstrated that nude mice
reconstituted with CD4+ T cells depleted of the CD25+
subpopulation of cells developed spontaneous autoim-
mune disease [44]. Replenishment of the CD25+ cell
population prevented this development of autoimmune
diseases. This suggested the presence of a naturally
arising subset of T cells that acted to limit the response
to self-antigens [41]. Several more recent studies showed
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the severity of the disease [41,45-47] indicating that
Tregs suppress expansion of autoreactive effector cells.
Amyotrophic lateral sclerosis
ALS is a progressive neurodegenerative disease of
unknown origin that primarily affects upper and lower
motor neurons located at the ventral horn of the spinal
cord, brain stem, and motor cortex [48]. These regions
control voluntary muscle movement, leading to paraly-
sis, respiratory failure, and ultimately, death with disease
progression [49]. Although the etiology remains enig-
matic, many factors and genetic mutations contribute to
the pathobiology of the disease in some cases. In familial
ALS (fALS), mutation of genes such as those that en-
code Cu/Zn superoxide dismutase (SOD-1) on chromo-
some 21 or alsin that encodes a ras GTPase have been
linked to ALS patient populations [50,51]. Currently
over 20 different genes have been associated with fALS;
however, the majority of ALS cases are sporadic and not
linked to familial or genetic factors. As a contributing
factor, neuroinflammation is thought to play a promin-
ent role, and is supported by evidence of reactive micro-
glia and astrocytes as well as infiltrating T cells found at
affected sites and implicated in disease pathogenesis
[52]. The interplay between nervous and immune sys-
tems results in an inflammatory response, which can be
detrimental or protective depending on the disease state.
Activated Teffs have the ability to penetrate the BBB and
carry out their immune functions in the CNS [53], and
inflammation has been thought to play a crucial role in
the death of motor neurons [54], suggesting that perhaps
an aberrant adaptive immune response is occurring.
Substantial numbers of infiltrating T cells and macro-
phages are found in the spinal cords of patients [55,56].
The majority of these migrating T cells are described as
CD8+ cytotoxic T cells with CD4+ T cells usually com-
prising a minority of lymphocytes. A considerable num-
ber of T cells are in close proximity to vessels near sites
of neurodestruction [57], while little or no T cell infil-
tration is found in spinal cords of controls. An im-
munohistochemical study by Engelhardt et al. found
both perivascular and intraparenchymal lymphocytic
infiltrates in the post-mortem spinal cords of 18 ALS
patients [6]. Virtually all lymphocytes were T cells with
little B cell infiltration, suggesting a T cell specific me-
chanism of destruction. Mostly, activated CD4+ T cells
were found near degenerating spinal tracts in ALS
patients [58]. Apart from direct migration into affected
areas such as the spinal cord, more immune aberrations
have also been documented in the periphery. For in-
stance, the frequencies of CD4+ T cells are increased in
the peripheral blood of sporadic ALS patients as well as
increased expression of antigen presenting moleculeslike HLA class II on APCs, suggesting systemic immune
activation in those patients [59]. While these changes
are found primarily in the periphery, those occurring in
the CNS may be quite different. Indeed, Teff types found
infiltrating the CNS were characteristic of Th17 and
Th1, suggesting the involvement of IL-17, IFN-γ, TNF-α
and IL-6 proinflammatory cytokine production and roles
for both Th17 and Th1 in ALS progression [60]. These
proinflammatory cytokine-producing CD4+ cell types
were increased in ALS patients compared to controls, as
well as IL-17 producing cells and total levels of IFN-y,
thus suggesting that the increased proinflammatory mi-
lieu plays a substantial role in exacerbation of motor
neuron death. On the other hand, T cells expressing
neurotrophic factors such as BDNF were also increased,
which suggested that although Th1 and Th17 Teffs
dominate the response in progressive ALS, neurotrophic
responses also may be involved in determining the
tempo of disease progression.
In addition to the increase in Teff populations and
pro-inflammatory cytokine levels associated with ALS
progression, Treg (CD4+CD25+) levels are decreased in
peripheral blood and are correlated with increased dis-
ease progression [61]. Since Tregs possess the capacity
to harness overactive immune responses, reduction of
Treg levels may indicate a deficit in the ability of the
patient to suppress an overactive and aberrant immune
response. To support that notion, one study found that
the numbers of Tregs and FOXP3 protein expression
were reduced in progressive ALS patients, and this
reduction correlated with disease progression [62]. Thus,
these data suggest the importance of FOXP3 to bestow a
functional ability of Tregs to suppress Teff subsets, and
lack of FOXP3 expression could result in aberrant im-
mune responses that may accelerate disease progression.
Studies using animal models of ALS show that Teffs
and Tregs play differing roles in the pathobiology of
ALS. In a study carried out by Beers et al., T lympho-
cytes were observed infiltrating into lumbar regions of
the spinal cord, as well as the cervical regions during
disease progression. Initially, the T cell subset was
considered Th2 due to the predominant expression of
GATA3 transcription factor [63]. However, as the disease
progressed, IFN-γ and T-bet were upregulated, which
are indicative of a Th1 phenotype, suggesting that T cell
subsets modulate with disease progression or vice versa.
This shift may also correlate with a shift in microglial
state. At an early disease stage, microglia show a protec-
tive M2 phenotype, but with disease progression, micro-
glia shift towards a pro-inflammatory or neurotoxic M1
phenotype [64]. Also, in mutant SOD1 G93A mice,
numbers of CD4+ and CD8+ T cells increase, as well as
activation of microglia, and inclusion of the mutant
SOD1 gene onto mice without functional T cells or CD4+
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or CD4+ T cells are beneficial in SOD1 mice [65,66].
However, increases in CD8+ T cells are typically seen
only in late stage ALS [66], whereas CD4+ increases are
seen earlier, suggesting an interplay between immune
activation and neurodegeneration in this disease. In one
study, knocking out CD4+ cells decreased microglial re-
activity suggesting a direct interaction between CD4+
T cells and glial cell activation [66]. However, another
study showed conflicting results, wherein mutant SOD1
mice lacking functional CD4+ T cells presented acce-
lerated motor neuron degradation, suggesting the im-
portance of CD4+ T cells for neuroprotective effects in
ALS [67]. Alternatively, this data may support a role for
the neuroprotective capabilities of CD4+CD25+ Tregs
and potentially other CD4+ subtypes. Therapeutic vac-
cination for motor neuron disease has also been ad-
dressed using Copolymer 1 (Cop-1, glatiramer acetate,
GA), which has been shown to mediate a protective
T cell response. Treatment with Cop-1 protected motor
neurons against degeneration and doubled the number
of surviving neurons when compared to untreated con-
trols [68]. On the contrary, a conflicting study showed that
therapeutic vaccination with a high molecular weight
derivate of GA does not alter survival and does not confer
neuroprotection in mutant SOD mouse models [69].
Besides the detection of a Th1 phenotype and increased
microglial reactivity in ALS mouse models, the benefits of
Treg-mediated protection of motor neurons have been re-
ported. In mSOD1 mice, Treg numbers that produce IL-4,
IL-10, and TGF-β are increased in early disease onset
suggesting that immunosuppressive capability may delay
disease progression [70,71]. Co-cultured with Teffs, Tregs
from animals in early stages were effective at inhibiting
proliferation using cytokine mediators. However, later in
disease, Treg numbers were decreased, and the ability to
inhibit Teff proliferation was diminished suggesting a
functional deficit in those Tregs [70,71]. Indeed, disease
progression accelerated with diminished Treg function.
Together, these data support the importance for Treg-
mediated suppression of detrimental immune responses
associated with the disease and in slowing the tempo of
disease progression. Another study from our own labora-
tory, using T cell adoptive transfer into the mutant SOD1
G93A model, found that transfer of either activated Teffs
or Tregs from wild-type mice delayed disease onset, loss
of motor function, and extended survival [14]. Moreover,
only transfer of Tregs delayed onset of clinical signs,
whereas transfer of Teffs increased the latency between
disease onset and entry into late stage disease. These re-
sults indicate that CD4+ T cells, regardless of phenotype,
may induce some protection in the mouse model of ALS
depending on the stage of the disease. For instance, during
early stages of disease, CD4+ Tregs may enhance M2,instead of M1 microglial phenotypes. However, at end
stage of disease when cytotoxic CD8+ T cell numbers
are found to increase and Treg-mediated neuroprotective
capabilities are diminished [67], transfer of anti-CD3
activated Teffs may function at several levels such as
increased production of anti-inflammatory mediators or
increased FAS-mediated lytic capabilities that can both act
on either activated microglia or neurotoxic Teffs.
Another neuroprotective strategy is the selective knock
down of mutant SOD1 in neuronal and non-neuronal
cell types of the CNS. In order to determine whether
diminution of mutant SOD levels affected disease pro-
gression, mice carrying deletable mutant genes were uti-
lized. Deletion of mutant SOD1 from motor neurons
delayed onset of disease and progression through early
stage [72,73]. Because glial activation is an accepted
hallmark of mutated SOD1 in ALS, researchers began to
address levels of mutant protein expression in glial cells
and their effect on disease. Selective deletion of mutant
SOD1 in microglia resulted in extended survival due to
the significant delay of post-onset disease progression
beyond that observed in selective deletion from motor
neurons [72,73]. Deletion of mutated SOD1 in astrocytes
while delaying activation of microglia, did not affect dis-
ease onset or early stage disease, but delayed late stage
disease progression [74]. Together, these data suggest
that limiting mutant levels in both neurons and non-
neuronal cell types slow disease onset and progression
and increase survival. Thus therapeutic targeting of mu-
tant SOD1 expression by microglia or astrocytes may
prove beneficial in the treatment of ALS.
Alzheimer’s disease
AD is the most common form of dementia-producing
neurodegenerative disorders. Pathologically, cortical and
subcortical neurons and synapses are preferentially and
progressively lost with histological hallmarks of neuro-
fibrillary tangles and extracellular amyloid-beta (Aβ) pla-
ques [75]. The formation of these histological hallmarks
is thought to contribute to neuronal death in areas such
as the hippocampus and cortex resulting in several be-
havioral and cognitive impairments. Disease risk factors
include both genetics and environment. Moreover, in-
creased neuroinflammation due to microglial responses
from neuronal loss and aberrantly cleaved and folded
protein components is implicated as well as BBB dys-
function and lymphocyte infiltration [76].
Indeed, multiple studies suggest that neuroinflamma-
tion in the CNS of AD patients is associated with
increased T cell infiltration [76-79]. Immune profiling of
peripheral blood from AD patients shows significant
aberrations in immune populations which may be asso-
ciated with disease progression [80]. T cells and B cells
are diminished, with substantial changes in CD4+ and
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cant decrease in the frequencies of naïve CD4+ T cells,
with concomitant increases in effector memory T cells
in AD patients [81]. Frequencies of CD4+CD25+ Tregs
were also reduced. Another study confirmed the de-
crease in total CD3+ T cells as well as decreased numbers
of B cells [82]. Interestingly, CD4+ T cell subsets were
increased while CD8+ T cell numbers were decreased.
However, other studies have detected no significant
changes in CD8+ T cell numbers or cytokine levels in
AD patients [83]. Additionally, the levels of different
T cell subsets detected are greatly variable, but each
study documents some systemic immune aberrations in
a CD4+ T cell population. One study noted, in combi-
nation with T cell subset changes, CD8+CD28- sup-
pressor cells were decreased among PBMCs from AD
patients, as well as IL-10 production [84]. These data
suggest that the immunosuppressive capabilities in AD
patients are diminished and could represent a deficit in
the ability to control Teff responses. Similarly, increased
activities of Th17 and Th9 subsets have been found in AD
patients [85]. Indeed, levels of the proinflammatory cyto-
kines IL-21, IL-6, and IL-23, and the Th17-associated
transcription factor RORγ, were increased among lym-
phocytes in AD patients. Moreover, IL-9 was produced in
significantly higher levels by cells from AD patients.
Together, these data are indicative of increased levels of
functional Th17 and Th9 phenotypes, which may lead to
profound skewing of an inflammatory immune response
in those patients.
Animal models of AD have shown increased numbers
of infiltrating neutrophils, macrophages, and T cells into
the CNS from the periphery, possibly through BBB
dysfunction [86,87]. Specifically for T cells, Th1 cells
secreting IFN-γ and Th17 cells producing IL-17 were
present in the CNS in amyloid precursor protein/presenilin
1(APP/PS1) mutant mice [88]. Interestingly, peripheral
immune activation using respiratory infection also in-
creased T cell infiltration into the brains of AD mice [89].
In those animals compared to controls, frequencies of
CD3+ T cells were significantly increased as well as those
of CD4+ and CD8+ T cells, proinflammatory Th1 and
Th17 Teffs, microglia, and expression of pro-inflammatory
genes encoding TNF-α, IL-1β, and IL-6. These increased
levels of proinflammatory immune cells and mediators
corresponding to increased levels of soluble and insoluble
Aβ as well as increased numbers of plaques. Another
study, in a rat model of AD, showed increased IL-17 and
IL-22 cytokine production in the hippocampus that further
supports the role of Th17-mediated promotion of micro-
glial activation leading to increased neuroinflammation
and neurodegeneration in AD and AD models [87]. To-
gether, these data suggest that specific Teffs may provide
neurotoxic conditions such that they contribute to theinflammatory cascade associated with AD and exacerba-
tion of disease progression. Additionally, blood vessels
near Aβ deposits express high levels of intercellular adhe-
sion molecule-1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1), contributing to the extravasation
of activated, antigen-specific (Aβ) T cells from the periph-
ery [90]. Possibly, drainage of inflammatory mediators
with aggregated and modified Aβ from the CNS provide
sources of activating agents and modified self-antigen for
APCs such as dendritic cells to induce Aβ-specific T cells.
In turn, activated T cells could enter the CNS to inflamed
sites via gradients of chemokines and cytokines that re-
cruit immune cells or, alternatively, a few activated T cells
could enter the inflamed area and in a paracrine manner,
create the pro-inflammatory milieu themselves necessary
to recruit and initiate other activated CD4+ T cells. On
the other hand, T cell entry into areas of Aβ deposits has
been observed to be beneficial in some cases [91]. Primary
cell line data indicated that Th2 cells inhibit Th1- and
Th17-mediated toxicities by decreasing IL-1β and IL-6
production, suggesting that this subset has regulatory and
anti-inflammatory capacities. Active immunization using
Aβ42 in a mouse model of AD enhanced clearance of
Aβ plaques [92], and was thought to induce anti-
inflammatory Th2 Teffs which increased neutralizing and
clearing anti-Aβ antibodies. Therefore, to enhance Aβ
clearance and downregulate the detrimental proinflamma-
tory cascade in AD patients, an Aβ vaccine approach was
thought a promising therapeutic strategy. However, after a
successful phase 1 trial that immunized AD patients with
Aβ1-42 peptide (AN1792) and QS21 adjuvant [93], a
phase 2a clinical trial yielded a proportion of patients
that experienced subacute meningoencephalitis [94]. Post-
mortem evaluation of patients revealed that the vaccine
had markedly cleared Aβ plaques, however neurofibrillary
tangles remained [95]. Moreover, T cell infiltration and in-
flammation near blood vessels were also observed in post-
mortem tissues, suggesting that vaccination may generate
T cells capable of infiltrating the CNS and exacerbating
the pathology associated with AD.
Parkinson’s disease
PD is characterized by the progressive loss of dopami-
nergic neurons that originate within the substantia nigra
(SN) and innervate the striatum resulting in the loss of
dopamine, thus causing a majority of the motor symp-
toms associated with PD [96]. Lewy bodies (LB) and
Lewy neurites (LN), two hallmarks of PD, are intracellu-
lar inclusions consisting of modified and misfolded
alpha-synuclein (α-syn) as well as ubiquitin [97,98].
These hallmarks present themselves in both sporadic and
familial cases of PD. Familial PD accounts for approxi-
mately 10% of all PD cases and several genes have been
identified in patients with a family history of PD. Six genes
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PINK1, DJ-1, ATP13A2, and Parkin [99]. While the loss
of neurons and dopamine explains the motor function
disturbances, the underlying driving force behind the
progression of PD is still unknown. However, works
performed by many researchers provide strong evidence
for the involvement of the immune system in PD and
neurodegeneration.
Initial studies of peripheral lymphocyte populations
from PD patients showed decreased frequencies and
total numbers of CD4+ T lymphocytes compared to
controls [100-103]. Due to conflicting reports from only
a few studies on T cell phenotypes, a firm consensus of
other T cell subset changes in PD patients has proven
difficult. For instance, the diminution of CD4+ T cell
numbers in PD patients was found chiefly from de-
creased numbers of CD4+CD45RA+ naïve T cells and to
a lesser extent from CD4+CD29+ memory subsets [100],
whereas, Stevens and colleagues reported decreased
levels of CD4+CD45R0+memory T cells [103]. A recent
study by Saunders and colleagues showed slight, yet
significant increases in frequencies of CD4+CD45R0+
memory/effector T cells with concomitant diminution of
CD4+CD45RA+ resting/naïve T cell levels [102]. Ad-
ditionally, frequencies of peripheral CD4+ T cells with
effector-associated phenotypes such as FAS + were in-
creased in patients, whereas those expressing α4β7 integ-
rins and CD31 (PECAM1) were diminished. Notably,
these changes in CD4+ T cell phenotypes were correlated
with severity of motor function as scored by the Unified
Parkinson’s Disease Rating Scale, part III (UPDRS III).
Differences in these immunological profiles among the
few reports may range from the heterogeneity of disease
to individual laboratory methodologies, but clearly require
further investigation to attain consensus profiles.
Post-mortem studies of PD patient brain tissues
showed both CD4+ and CD8+ T cells in close proximity
to dopaminergic neurons within the SN at levels excee-
ding 10-fold those found in brains of controls [104].
Moreover, these levels of T cells were not detected in
non-lesioned brain regions. Microarray analysis of per-
ipheral blood leukocytes and SN brain tissue showed
many genes expressed were in common with those
expressed by Th17-mediated immune reactions and sug-
gested to the authors that idiopathic parkinsonism is a
Th17 dominant autoimmune disease [105]. However,
whether T cell infiltration is primary or secondary to PD
progression is still unclear. Similarly, conflicting reports
of Tregs in PD are also wrought with variances in levels
detected ranging from increased frequencies in PD
patients compared to controls to little or no differences
[13,100-102,106]. However, one study demonstrated the
diminished capacity of Tregs from PD patients com-
pared to those of controls to inhibit the proliferation ofresponder T cells from healthy donors [102]. This
suggested that a dysfunction in Tregs leads to a hyper-
activated immune state and increased disease progres-
sion. The notion that hyper-activated immune responses
support increased dopaminergic loss was provided by
animal studies.
Multiple studies in animal models have demonstrated
the involvement of the adaptive immune system in dopa-
minergic neurodegeneration using both active and passive
transfer of immunity [13,104,107]. In the 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse mo-
del, numbers of T cells in the SN are increased after
intoxication, and interestingly, numbers of CD8+ T cells
predominate those of CD4+ T cells. While in agreement
of the relative proportions of T cell subsets within the SN
of MPTP-treated mice, the total numbers of CD4+ T cells
vary widely between studies. The importance of T cells to
MPTP-induced neurodegeneration was found initially in
adoptive transfer and reconstitution studies of functional
T cells to immune deficient mice [104,108]. While both
studies confirmed that immune deficient mice were not
susceptible to MPTP intoxication, reconstitution of those
mice with functional naïve lymphocytes partly restored
MPTP susceptibility [108] and CD4+ T cells were chiefly
responsible for MPTP susceptibility [104]. These studies
point to a deleterious role of CD4+ T cells in PD, unlike
the beneficial role they play as described in ALS; however
in the former, those T cells were determined to be Th1
and Th17 effector T cells. Of primary importance to these
studies was the finding that immune T cells could
augment MPTP-induced neuroinflammation and neuro-
degeneration verified through the use of mice lacking
CD4+ T cells [104]. T cells from mice immunized with
a modified self-antigen, nitrated α-synuclein (N-α-syn)
recognized only N-α-syn, but not unmodified α-syn in
in vitro challenge assays. Moreover, N-α-syn specific Teffs
exacerbated neuroinflammation and increased neuronal
injury and subsequent neurodegeneration of dopaminergic
neurons within the SN of MPTP mice [108]. These fin-
dings indicate that N-α-syn, as a modified self-protein,
either evades or breaks immunological tolerance to self
α-syn and induces N-α-syn specific T cells. Indeed, by po-
larizing N-α-syn specific CD4+ T cells into different Teff
types and adoptively transferring each separate Teff type
into MPTP mice, another study showed that Th17 Teffs
possess a significantly greater capacity to exacerbate
dopaminergic neurodegeneration than the same number
of Th1 Teffs [13]. Together, these data indicate that CD4+
T cells play an important role in the neuroinflammation
and subsequent neurodegeneration in models of PD and
that Th17 Teffs are more potent at direct killing of
neurons or alternatively, enhancing neurotoxic microglia.
These data also support the notion that peripherally circu-
lating Teffs, as found increased in PD patients, are capable
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exacerbate and accelerate PD disease progression.
Activated microglia and Teffs are thought to be media-
tors of neuroinflammatory processes in PD progression.
Left uncontrolled, these mediators support an inflam-
matory cascade that affects the tempo of disease [12].
Initially, studies directed to harness the inflammatory cas-
cade demonstrated that adoptive transfer of CD4+ T cells
from copolymer-1 (Cop-1) immunized donor mice pro-
tected dopaminergic nigral neurons and striatal termini in
MPTP-treated mice [109]. These observations supported
the hypothesis that subpopulations of T cells mitigate neu-
rodegeneration in the MPTP animal model of PD. These
findings are congruent with known mechanisms by which
Cop-1 regulates proliferative and inflammatory responses
by preferentially inducing Th2, Th3, and Tregs that secrete
anti-inflammatory cytokines [12,50,51,109,110]. In a sepa-
rate line of study, researchers found that CD4+CD25+
Tregs were most capable of suppressing neuroinflamma-
tion and neurodegeneration in the MPTP model with as
few as 3.5 × 106 Tregs being sufficient to provide virtually
complete neuroprotection to dopaminergic neurons along
the nigrostriatal axis [12]. Moreover, the degree of protec-
tion afforded by Tregs seems to increase with increasing
inflammatory responses as evidenced by increased neuro-
protection with Treg co-transfer with N-α-syn Th17 in the
MPTP model [13]. Moreover, use of vasoactive intestinal
peptide (VIP), a known inducer of Treg activity [99] in-
creased the neuroprotective capability of Tregs from VIP-
treated donors in the MPTP model [13]. In that same vein,
studies using granulocyte macrophage colony stimulating
factor (GM-CSF) showed that treating animals with GM-
CSF prior to MPTP-intoxication increased Treg activity in
a dose dependent fashion as well as diminished the
neuroinflammatory response and provided significant
dopaminergic neuroprotection [111]. Taken together, the
results here and from PD patients formed the basis for a
clinical strategy (ClinicalTrials.gov: NCT01882010) to tar-
get dysregulated Treg function in PD patients with GM-
CSF (Leukine, sargramostim) to upregulate Treg numbers
or function that will suppress neurotoxic Teff and micro-
glial immune responses and afford a neuroprotective
outcome that inhibits or slows PD progression [2,111].
As previously discussed, each neurodegenerative dis-
ease has different pathological hallmarks. The cellular
location of these hallmarks varies from primarily intra-
cellular in PD and ALS to primarily extracellular debris
in MS and AD; however it should be noted that in-
tracellular inclusions eventually become extracellular,
especially upon neurodegeneration. Additionally, T cells
generally do not recognize and respond to extracellular
antigen and debris, but depend on the presentation of
an antigen in the context of MHC or to bystander effects
from glial cells. To our knowledge, no studies implicatedifferent types of T cells or T cell responses in relation
to both intracellular and extracellular pathological hall-
marks. Thus, an interesting hypothesis asserts that the
extent of external debris processed during disease pro-
gression could influence the overall scope of T cell
responses. A most notable ramification of this notion is
the putative importance that animal models do not
present all the pathological hallmarks distinct for each
disease. Nonetheless, animal models do provide re-
searchers with the ability to assess pathology, etiology,
and overall disease progression within the limits of the
model, and represent indispensable tools to develop and
test potential therapeutics.
T cell migration to sites of inflammation
The adaptive immune system functions to aid in effec-
tive clearance of foreign antigens by recognizing antigen
presented in the context of an MHC molecule. Most
efficacious immune responses occur in close proximity
to the foreign antigen (e.g., cell-mediated lysis of infected
cells). To gain proximity, circulating lymphocytes mi-
grate across luminal barriers to gain entry to sites of
infection or inflammation. Successful extravasation of an
activated T cell from circulation to an area of inflamma-
tion is dependent on cell adhesion molecules (CAMs)
and CAM ligands. These specialized binding partners
expressed on both circulating T cells and endothelial
cells (ECs) are critical to recruitment of proper immune
cells to the site of inflammation. However, due to the
BBB, migration of cells into the CNS and inflammatory
sites therein presents a formidable exercise in mobility.
The EAE model provides a prototypical system for the suc-
cessful interaction of antigen specific CD4+ effector T cells
with ECs and altered CAM expression to facilitate entry
into the CNS and cerebral spinal fluid (CSF) [6,112,113].
Disease and CAM expression
T cell migration across any EC barrier, and particularly
across the BBB requires a distinct set of steps; each step
mediated by different CAMs on both T cells and ECs
[6,114]. Under normal conditions, expression of CAMs
by brain ECs is minimal or completely lacking [6-8,115].
However, under inflammatory conditions, ECs are acti-
vated by cytokines and upregulate CAM expression.
Assessing the infiltration of circulating lymphocytes
across ECs has shown that the expression of CAMs and
cell adhesion ligands changes following antigen activa-
tion and/or cytokine release. These changes typically
precede disease onset and either increase or decrease
binding of circulating lymphocytes to target endothe-
lium. Furthermore, studies have shown that, under dis-
ease states including MS, viral encephalitis, and stroke,
specific CAMs are upregulated [7,8] lending evidence
that the immunological processes associated with these
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sion of CAMs, and thus, provide strategic targets for
therapy. Indeed, the ability to transfer EAE using myelin
basic protein (MBP)-TCR transgenic T cells was de-
pendent on the expression of glycosylated ligand for
P-selectin, PSGL-1 [9,116]. This ability was proposed to
correlate with the upregulation of PSGL-1 on their
surface. In MS patients, greater numbers of peripheral
CD4+ T cells are found that express higher surface levels
of PSGL-1 than in controls, suggesting an enhanced cap-
acity to interact with CNS ECs in a PSGL-1 dependent
manner [6,9]. Another adhesion molecule previously de-
scribed as a novel marker associated with tumor meta-
stasis, melanoma cell adhesion molecule (MCAM) was
found to play a role in migration of Th17 cells in
EAE [117].
Antigen-induced CAMs
The co-culture of lipopolysaccharide (LPS), a component
of gram-negative bacteria, with ECs induces upregulation
of multiple CAMs on the luminal side (ICAM-1, VCAM-1,
endothelial (E)-selectin) in a time and concentration-
dependent manner [118,119]. These data, combined with
the sensing of LPS as MAMPs, show that induction of
microglial activation, neurotoxic factor production, and
significant dopaminergic neurodegeneration provided evi-
dence for LPS as an animal model of nigral dopaminergic
neurodegeneration [113,120-122]. Other molecules also
have shown similar capabilities as LPS. Within the SN of
PD patients, N-α-syn accumulates within neurons and is
one component of Lewy bodies. When released into the
extraneuronal environment, microglia detect N-α-syn as
DAMPs and elicit a proinflammatory phenotype that is
neurotoxic and accelerates the death of dopaminergic
neurons [59,123-126]. The ability to induce a proinflam-
matory response by microglia suggests that aggregated or
N-α-syn may act as a neo-antigen and stimulate APC
function by dendritic cells in draining tissues or even resi-
dent brain microglia resulting in sustained activation of
microglia [108,127]. Moreover, those studies showed
within 20 hours after MPTP-intoxication, N-α-syn is
detected within draining cervical lymph nodes, wherein
APCs are upregulated and later elicit peripheral adaptive
immune responses. Furthermore, evidence that N-α-syn-
specific CD4+ Teffs accelerate disease progression was
suggested by increased neuroinflammation and subse-
quent dopaminergic neurodegeneration after adoptive
transfer of N-α-syn specific T cells. However, the mechan-
ism(s) by which those Teffs function and whether they
must cross the BBB are not entirely understood. Models
that address a prominent role of CD4+ Teffs in driving
inflammation implicate infiltrating Th17 Teffs that possess
unique migratory properties and expression of MCAM for
tissue entry [117].Aβ as an inducer of CAM expression
While the exact mechanism of T cell infiltration across
the BBB remains unknown in AD, multiple studies have
addressed this topic. As discussed, patients with AD dis-
play large accumulations of Aβ plaques in the brain, and
Aβ-specific T cells have been shown to effectively mi-
grate across the BBB. In an APP/IFN-γ Tg mouse model,
Aβ immunization resulted in migration of both CD4+
and CD8+ T cells into the brain parenchyma [128].
Quantitation and analysis showed the majority of those
T cells were antigen-specific, CD4+ T cells with a Th1
phenotype, characterized by their predominate secretion
of IFN-γ. Thus far, the mechanism by which circulating
lymphocytes migrate into the CNS in AD is unclear, but
upregulation of different CAMs associated with transen-
dothelial migration has been documented in both animal
models of AD and AD patients. For instance, peripheral
T cells from AD patients overexpress macrophage in-
flammatory protein-1α (MIP-1α), which induces expres-
sion of CCR5 on human brain microvascular endothelial
cells, ultimately leading to enhanced migration across an
artificial BBB [129]. Another study showed that com-
pared to age-matched controls expression of CXCR2
was increased on peripheral T cells from AD patients
[130]. In that study using AD models, increased expres-
sion of CXCR2 was dependent on levels of microglial-
derived TNF-α and enhanced T cell entry into the CNS.
In both studies, inhibition of the receptor-ligand interac-
tions through the use of antibodies or antagonists effect-
ively blocked T cell entry in transendothelial migration
assays, further supporting the concept that blockade of
cellular adhesion molecules in AD could inhibit extrava-
sation of pro-inflammatory, and possibly detrimental,
antigen-specific T cells into the CNS. In a later study,
the role of enhanced CCR5 expression in promoting
T cell migration was verified in migration assays, and
further showed that Aβ interaction with RAGE, an Aβ
receptor, induces CCR5 upregulation on brain endothe-
lial cells [79,129]. Moreover, animal studies showed that
intracerebroventricular injection of CD4+ T cells into
the brain parenchyma increases ICAM-1 expression by
brain endothelial cells, further suggesting that a putative
mechanism for T cell transmigration in AD would
encompass CAM modulation and interaction by both
T cells and endothelial cells [131].
Mutant α-synuclein and CAMs
Two studies demonstrated that wild type (WT) α-syn and
mutant forms of α-syn (A30P; E46K; A53T) can alter the
expression levels of ICAM-1 and CD44 on human astro-
cytes, astrocytic cell lines, and murine microglial cell lines
[10,11]. The upregulation of CD44, a binding partner for
E- and P-selectin was shown to correspond with an in-
creased migratory capacity of microglial cells both in vivo
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α-syn can regulate microglial migration into the SN,
accelerating the pathogenesis of PD [10,11]. These studies
provide evidence that α-syn is capable of altering CAM
expression and that a therapeutic approach to block CAM
expression could provide a beneficial outcome in PD
patients.
CAM involvement in T cell infiltration to CNS
Activated CD4+ T cells, compared to naïve CD4+ T cells,
circulate within the vasculature differently [132] and have
the capacity to cross the BBB. Studies using adoptive
transfer of MBP-specific T cells in the EAE model showed
that VCAM and ICAM-1 were upregulated by those cells
by 48 hours after transfer [98]. In MS lesions, altered
levels of adhesion molecules and their respective ligands
have been identified on endothelial cells and perivascular
inflammatory cells [27]. Specific blocking of either α4-
integrins or VCAM-1 inhibits the development of EAE,
indicating that α4-integrin interactions with VCAM-1 play
a critical role in the recruitment of Teffs across the BBB
[133,134]. Natalizumab, a drug indicated for relapsing-
remitting MS, is a human monoclonal antibody that spe-
cifically blocks the α4 subunit of integrins and has yielded
favorable clinical outcomes [135]. A marked increase in
ICAM-1 was found within the SN at sites of T cell infiltra-
tion following MPTP-intoxication [104] and numbers of
peripheral CD4+ T cells that expressed α4β7 integrin were
diminished and inversely correlated to clinical severity in
PD patients [102] suggesting that Teffs are removed from
the peripheral circulation, either by elimination or dissem-
ination to sites of CNS inflammation, and may play a role
in disease progression. However, until recently, no studies
have adequately addressed or evaluated CAM changes
within the SN of PD patients or in mouse models of PD.
Mechanisms of T cell-mediated destruction and
protection
Based on interactions between T cells and surrounding
immune cells, T cells can play a neuroprotective or neuro-
degenerative role in several diseases discussed (Figure 1).
The cross-talk between T cells and glial cells is thought to
help mediate effector functions by either cell-cell contact
or cytokine-mediated mechanisms. Possible neurodestruc-
tive mechanisms include direct cytotoxicity by proin-
flammatory cytokines, hyperactivation of proinflammatory
microglia, or diminished suppressive function of Tregs.
On the other end of the spectrum, targeting T cells to
elicit a protective mechanism, could diminish the extent
of neuroinflammation and therefore increase the number
of surviving neurons in the CNS of patients with neurode-
generative disorders. The number of potential targets to
elicit neuroprotection is extensive and will be discussed in
further detail in the following sections.T cell-glial interactions and neurodegeneration
During viral infections and neuroinflammation, MHC II is
upregulated by microglia, whereas MHC I is constitutively
expressed by most cells including oligodendrocytes, neu-
rons, microglia, and endothelia [136]. Therefore, neurons
in a pro-inflammatory environment could serve as targets
for CD8+ T cells with direct killing of neurons through
antigen-specific interactions mediated by cytotoxic gran-
zyme release [136]. In animal models of MS, studies de-
monstrated that CD8+ CTLs form stable adhesions with
neuritis in a MHC I peptide-dependent fashion. Fur-
thermore, MBP-specific CD8+ T cells induce direct tissue
damage when injected into irradiated recipient mice [137]
(Figure 1). Increased numbers of CD8+ T cells are found
in close proximity to activated microglia in post mortem
studies of PD patients [104], however their role in PD
and PD animal models remains enigmatic. The presence
of T cells within the brain of PD patients exceeds those
typically found in the CNS and suggests a role of the T
cell beyond normal surveillance [138]. These studies,
taken together, suggest a strong role of MHC I restricted
CD8+ T cells in the pathogenesis of neurodegenerative
disorders that may involve not only disease progression,
but also initiation of disease events.
The probability exists that multiple T cell subsets other
than CD8+ Teffs play a role in inflammation-associated
neurodegenerative disorders (Figure 1). MHC II restricted
CD4+ Teffs appear to play a detrimental role in neurode-
generative disease pathogenesis. CD4+ Teffs recognize
antigen presented by MHC II expressing microglia within
the CNS resulting in the activation of resident immune
cells. Examples of the self-reactive antigens believed to be
involved in T cell activation include N-α-syn in PD [13],
Aβ in AD [88], and MBP in MS [139] (Figure 1). These
microglial-T cell interactions induce reactive microglia to
release neurotoxic factors that ultimately damage the
neuron and drive the neuroinflammatory cycle. Whereas
one EAE study showed CD8+ T cells in close proximity to
activated microglia and that CD8+ T cells induce direct
neuronal damage via recognition of antigen in a MHC
dependent fashion, T cells in another study were detected
directly attached to neurons, although independent of
MHC molecules, and elicited cytotoxicity via a glutamate-
mediated mechanism [140]. This suggests a possible direct
neurotoxic T cell-mediated mechanism that may not re-
quire recognition of self-antigen in the context of MHC.
The association of T cell-mediated enhanced microglial
function was recently demonstrated by depletion of CD4+
T cells from SOD-1 mutant mice that resulted in signifi-
cant diminution of CD11b+ immunoreactivity, thus sup-
porting the idea that direct T cell-microglia interactions
may potentiate neurodegeneration [141]. As discussed
previously in this review, CD4 knock out (KO) mice show
increased survival and decreased motor loss which may
Figure 1 The immune system and neurodegeneration. Death or damage of neurons can be mediated via several mechanisms in the CNS.
Upon insult, healthy neurons become damaged, causing release of self-antigens or modified proteins. These antigens remain in the CNS to
activate surrounding resting microglia to an activated phenotype. Reactive microglia produce proinflammatory mediators such as neurotoxic
cytokines and reactive oxygen and nitrogen species (ROS/RNS), increase oxidative stress, and further contribute to neuronal damage. Modified
and misfolded self-proteins that drain into secondary lymphoid tissues are phagocytized, processed, and presented on MHC by APCs to naïve
T cells (N). Upon recognition of antigen, T cells differentiate into antigen-specific T effector (Teff) or T regulatory (Treg) phenotypes. Teff subsets include
Th1 (1), Th2 (2), Th9 (9), Th17 (17), Th22 (22), and cytotoxic T lymphocytes (CTLs). Additionally, reactive microglia signal proximal endothelial cells by
cytokine and chemokine gradients to upregulate CAMs. In turn, activated Teffs such as Th1 and Th17 with upregulated integrins and CAM ligands
bind CAMs via CAM-ligand interactions and extravasate across the BBB. Upon recognition of modified self-antigen presented by MHC of microglia/
macrophages, activated Teffs generate neurotoxic and proinflammatory factors that drive M1 microglia or resting microglia to a higher reactive state
and support a neurotoxic cascade. CD4+ Th1 or Th17 Teffs induce FAS ligand or produce neurotoxic cytokines such as TNF-α, IL-17, and IFN-γ that
may directly interact with cognate receptors expressed by neurons. CD8+ CTLs can recognize antigen/MHC I complexes on neurons to induce
perforin- and/or granzyme-mediated cytolysis. In response to inflammatory events, Tregs (R) attempt to counteract the neurotoxic cascade through
inhibition of antigen presentation, production of anti-inflammatory cytokines, metabolic disruption, cytolysis of Teffs or reactive microglia, and
induction of neurotrophic factors by astrocytes; all mechanisms aim to interdict the neuroinflammatory-neurodegenerative cycle and ultimately
support neuronal survival.
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[66]. The detrimental effects of Th17 cells are known in
neurodegenerative diseases and their respective models
[142]. An underlying mechanism of Th17-mediated neu-
rotoxicity is through direct contact with neurons through
Fas-Fas ligand (FasL) interactions resulting in apoptosis
and neuronal death [87]. Glial cells within the CNS canalso act through the Fas-FasL interactions to inhibit or kill
infected cells and target activated lymphocytes or Teffs
that could yield neurotoxic events [1]. Thus, the loss of
potentially neurotoxic immune effector cells would eli-
minate those Teff-mediated killing mechanisms that act
directly on neurons or indirectly via microglial activation
and should prove to be neuroprotective. Furthermore,
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are known to contribute to inflammatory neurodegene-
ration [1].
Potentiating or mitigating neuroinflammatory circuits
are astrocytes, a glial subset that normally is involved in
the maintenance of brain homeostasis. However, in the
presence of hyper-activated microglia, astrocytes can
directly participate in inflammatory reactions to secrete
pro-inflammatory mediators such as IL-6 and TNFα,
upregulate expression of FasL, and diminish trophic ac-
tivities that eventually lead to the acquisition of a neuro-
toxic phenotype that exacerbates neurodegeneration
[143,144]. Similarly, while microglia that exist in an
alternatively-activated (M2) state are generally considered
neuroprotective and release anti-inflammatory cytokines
as well as neurotrophic factors, under neuroinflammatory
conditions, microglia can readily switch to an M1 cyto-
toxic phenotype (Figure 1). The phenotypic switch is
accompanied with upregulation of oxidative stress gener-
ating enzymes such as iNOS, NADPH oxidase, and mye-
loperoxidase; increased levels of reactive oxygen species
(ROS) and reactive nitrogen species (RNS); and secretion
of neurotoxic levels of proinflammatory cytokines includ-
ing IL-1β, TNFα, and IFN-γ [64] that lead to secondary
neuronal damage [145]. A recent study showed that in
MS patients proportions of Th22 cells correlated with
those of Th17 cells, serum IL-22 concentrations were
highest during peak phases of disease, and those levels
diminished during recovery phases [146]. In addition to
an essential role for Th22 and Th17 in MS, these data sug-
gested that the two Teff types may play synergistic roles in
disease progression and yielded speculation that since
IL-23 promotes IL-17 and IL-22 secretion, IL-23 receptor
and STAT3 signaling may provide a key pathway in the ac-
tivation of Th22 cells and Th17 Teffs. Moreover, activated
microglia proved to be a potent source of IL-23 expression
in active and chronic active MS lesions [147], suggesting
that microglia may provide the stimulatory signals respon-
sible for activation of Th17 and Th22 Teffs.
Treg targeted neuroprotection
As we have discussed, T cells play a dual role in neuro-
degeneration and neuroprotection during CNS disor-
ders. Early studies in models of nerve injury showed
improved recovery that coincided with the presence of
activated immune cells [145]. Therefore, targeting the
adaptive immune system could provide a potential stra-
tegy to halt neurodegenerative progression. Tregs are
potent immune modulators with the ability to suppress
the immune system through multiple mechanisms in-
cluding secretion of anti-inflammatory cytokines that
inhibit differentiation of Teffs; direct killing of Teff
subsets; blocking of co-stimulation of naïve T cells and
Teffs; and metabolic disruption of Teffs via uptake ofIL-2 [23,142] (Figure 1). Anti-inflammatory cytokines,
such as IL-4, IL-10, and TGFβ, are prime anti-
inflammatory mediators that diminish neuroinflamma-
tion and increase neuroprotection. Tregs isolated from
mutant SOD-1 mice and co-cultured with wild type
microglia suppressed NOX2 and iNOS production via
an IL-4 mediated mechanism [70]. Moreover, adoptive
transfer of those Tregs to T cell deficient ALS mice aug-
mented neuroprotection of motor neurons and extended
recipient survival. Additionally, neuroprotective me-
diators such as T cells that express anti-inflammatory
cytokines and neurotrophic factors were expressed in a
temporally and spatially distinct fashion depending on
the clinical scores and extent of histopathology [63,70].
Importantly, numbers of Tregs and FOXP3 expression
from ALS patients were reduced in rapidly progressing
ALS patients, inversely correlated with disease progression
rates, and were predictive of future rapid progression [62].
Multiple lines of evidence from our laboratories have
demonstrated the efficacy of several immunomodulators
in eliciting Treg-mediated neuroprotection in models of
neurodegeneration [12-14,51,109,111,148,149]. These im-
munomodulatory agents such as anti-CD3, VIP and
GM-CSF primarily act to increase Treg numbers and func-
tional capabilities that exploit Treg function to diminish the
neuroinflammatory cycle and provide neuroprotection.
Modulation of T cell CNS infiltration
T cell infiltration of the CNS has been demonstrated in
multiple neurodegenerative diseases [150]. This infil-
tration into the CNS is generally restricted to activated
T cells and occurs in a well-characterized and stepwise
manner [151] (Figure 2). CNS degenerative disorders
wherein T cell extravasation is thought critical for dis-
ease initiation and progression is best documented in
the EAE model. Blocking antibodies and multiple drugs
have been utilized to target specific subunits of CAMs
with the ultimate goal of blocking BBB migration of en-
cephalitogenic Teffs that are specific for the self-antigen
[27,135,151]. One consensus is that extravasation of T
cells in inflammation-associated neurodegenerative dis-
orders such as MS is dependent not only on the CAMs
and ligands utilized by ECs and T cells, but also on the
cellular architecture and the site at which T cells mi-
grate. This consensus is particularly critical to the notion
that migration of T cells across the BBB is necessary for
disease initiation or progression; however, others have
suggested that T cells may function in an endocrine or
paracrine fashion across a BBB that has become more per-
meable under inflammatory conditions [152]. In addition
to the conventional group of CAMs that regulate T cell
extravasation, a recent study identified MCAM (CD146)
expressed on Th17 Teffs and its ligand, laminin 411,
expressed within the vascular endothelial basement
Figure 2 Migration of activated T cells into brain. Peripherally, naïve T cells (N) encounter APC that present peptides from aberrant, misfolded,
or aggregated proteins associated with neuroinflammatory processes. Upon presentation of antigen and delivery of appropriate co-stimulatory
signals by APC, naïve T cells recognizing the antigen/MHC complex via the TCR become activated (A) leading to upregulation of CAMs on the
T cell surface. These receptors and ligands include, but are not limited to, integrins, MCAM, and PSGL-1. Similarly, at sites of neuronal injury and
neuroinflammation, danger signals, pro-inflammatory cytokines, and chemokines induce upregulation of endothelial associated CAMs on the
basolateral side of the blood brain barrier. Following upregulation of CAMs, activated T cells (such as pro-inflammatory, anti-inflammatory or
regulatory T cells) enter the vasculature and begin the process of extravasation via either a trans- or para-cellular route. This migratory process
occurs in a step-wise manner beginning with T cells loosely tethering to endothelial cells via the binding of T cell ligands to selectins, such as
E-selectin and other CAMs, such as VCAM, ICAM, and laminin 411 on the luminal side of the endothelial cells. Loose tethering allows the cell to
roll along the luminal side of the endothelium and interact with CAMs, pulling it closer to the endothelial cell layer to eventual capture. Upon
clustering of receptors and ligands on T cell and endothelial cell surfaces, the T cell begins “crawling” across the endothelial surface until reaching an
endothelial cell junction, which signals the initiation of extravasation. Transmigration proceeds, via a chemotactic gradient allowing antigen-specific
T cells entrance to the brain. Once in the parenchyma, activated T cells recognize antigen presented by MHC, initiating the efferent response program
of the T cells to deliver either effector or regulatory function that supports the respective neurodegenerative or neuroprotective outcome.
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in vitro interaction of MCAM and laminin 411, and ad-
ministration of anti-MCAM antibodies to recipient mice
prior to adoptive transfer of encephalitogenic Th17 Teffs
reduced Th17 cell infiltration and ameliorated disease in
EAE. These data suggested that MCAM expressed by
Th17 Teffs may provide a strategic therapeutic target for
inhibiting migration of neurotoxic Th17 Teffs and affor-
ding increased neuroprotection.
Novel insights for T cell responses in Parkinson’s
disease
Our laboratories have accumulated a substantial
amount of evidence indicating that adoptive transfer of
N-α-syn-specific Teffs after MPTP intoxication exacer-
bates neuroinflammation, enhances neurodegeneration,
and prolongs lesion development [2,13,108,111,127].
Recent evidence from clinical studies indicated that T
cells with an activated or memory/effector phenotypeare present in greater frequencies in PD patients com-
pared to age- and environment-matched caregiver con-
trols [102]. Increased proportions of those T cell subsets
were directly correlated with diminished motor function
and associated with diminished Treg function in PD pa-
tients. Taken together, the detection of CD4+ and CD8+
T cells within the SN of mice treated with MPTP and in
PD patients, the proximity of infiltrating T cells to MHC
expressing microglia/macrophages, and CD4/CD8 ratios
of infiltrating T cells that are reversed from those ex-
pected in peripheral circulation [13,51,97,104,108] pro-
vide strong evidence for the directed extravasation and
migration of activated T cells to sites of inflammation
and for the association of increased disease or lesion
progression with increased T cell infiltration. However,
whether extravasation and migration of T cells are
necessary and the mechanism(s) associated with T cell
migration in Parkinsonism have not been adequately
evaluated.
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infiltration into the CNS
To examine T cell migration under neuroinflammatory
and neurodegenerative conditions, mice were treated with
4 doses of MPTP, one dose every 2 hours. This dosage of
MPTP induces peak neuroinflammation and rate of
neuronal death by 48 hours of administration, both are
typically resolved by 4 days after treatment [97,153,154].
Anti-CD3-stimulated and 111In-labeled Teffs were adop-
tively transferred to MPTP- or PBS-treated recipients.
Animals were monitored by CT/SPECT every 24 hours
for 120 hours post- transfer. We previously demonstrated
that CD3 stimulated, 111In-labeled effector T cells did not
migrate into the CNS of naïve mice (data not shown).
In contrast, MPTP-treated mice consistently showed in-
creased percentages of radiolabel in the brain compared to
PBS-treated controls; however significant differences were
detected only after 24 hours post-transfer (Figure 3A).
Significant accumulation of labeled T cells were found in
lymph nodes of MPTP mice at most times (Figure 3F), but
only at 72 hours for cervical lymph nodes (Figure 3E). Dif-
ferences in brain and lymph nodes, 24 hours after adoptive
transfer of 111In-labeled Teffs, can be seen in movies of
CT/SPECT-imaged recipient mice that were treated with
either PBS (Additional file 1) or MPTP (Additional file 2).
These data suggested that activated T cells can preferen-
tially migrate to the CNS and peripheral lymphoid tissues
under inflammatory conditions. In contrast, significantly
greater accumulation of radiolabeled T cells were detected
in spleens from PBS-treated mice than in MPTP mice
(Figure 3D). While accumulation of fewer labeled T cells
was found in the spleen compared to other peripheral
lymphoid tissues, activated T cells could preferentially ac-
cumulate in more inflamed tissues or remain in circulation
rather than accumulating in the spleen. In a previous study
using only 5 × 106 111In-labeled activated Teffs and asses-
sing CT/SPECT at 24, 48, and 72 hours, no significant
differences in percentages of radiolabeled T cells could be
discerned between MPTP- and PBS-treated mice in any
tissue at any time (data not shown). Since adoptive transfer
of nitrated α-synuclein peptide (N-4YSyn)-specific Teffs
exacerbate neuroinflammation and neurodegeneration in
MPTP-treated mice [13,108], the previous data suggested
the possibility that a threshold number of T cells in the
brain is required for detection by CT/SPECT or that
T cells remaining in the encephalic vasculature were
masking those that migrated into the parenchyma.
CAM expression increases with MPTP intoxication and
adoptive transfer of T cells
Altered expression and recognition of CAMs and ligands
on ECs and leukocytes are the primary mechanisms by
which activated T cells extravasate from circulation to
brain parenchyma [151]. One such CAM that is associatedwith expression by Th17 Teffs is MCAM (CD146), a
member of the immunoglobulin superfamily of CAMs
[155]. Expression of MCAM by CD4+ Th17 cells has been
implicated in playing a major role in the extravasation of
Th17 cells in EAE [117]. Therefore, these studies sought
to evaluate MPTP-induced alterations in the expression of
MCAM on activated T cells. Donor CD3+ T cells (Thy 1.1
or CD90.1) were activated with anti-CD3. Activated donor
T cells (Thy1.1) were adoptively transferred to MPTP- or
PBS-treated recipients (Thy 1.2 or CD90.2). Spleens and
lymph nodes were removed from recipients and analyzed
by flow cytometric analysis for expression of CD4+CD146+
T cells within the transferred donor (Thy1.1) or the en-
dogenous recipient (Thy1.2) T cell populations. Prior to
adoptive transfer, little expression of CD146 was detected
among the stimulated donor T cells (Figure 4A). CD146
expression increased among CD4+ donor T cells by
48 hours post-transfer to either PBS- or MPTP-treated
mice. Interestingly, frequencies of CD146+ T cells were
increased among donor T cells from MPTP-treated re-
cipients compared to those from PBS controls. While no
differences in frequencies of CD4+CD146+ T cells were
detected among endogenous (Thy1.2) splenic T cells re-
gardless of treatment (data not shown), significant dif-
ferences were found in endogenous T cells from lymph
nodes (Figure 4B). By 24 hours post-MPTP or 48 hours
post-adoptive transfer with MPTP-intoxication, percen-
tages of endogenous T cells expressing CD146 significantly
increased. However, by 48 hours post MPTP-intoxication
in the absence of adoptive transfer, MCAM levels dimi-
nished to control levels, suggesting that MCAM expres-
sion is upregulated quickly, but transiently expressed after
an initial insult (e.g., MPTP intoxication) as are other
CAMs [156], and that activated T cells after homing to
sites of accumulation or inflammation may prolong the ex-
pression of MCAM by endogenous T cells. Taken together,
these findings indicate that adoptive transfer of activated T
cells to MPTP-treated recipients is sufficient to upregulate
MCAM expression on activated donor T cells as well as
recipient T cells; however, in the absence of initial insult,
expression is diminished or transient.
Potential role of MCAM in T cell migration
To evaluate the role of MCAM and T cell migration into
the CNS in the MPTP model, 111In-labeled donor Th17
Teffs were adoptively transferred to MPTP-intoxicated
recipients that were treated with anti-MCAM or isotype
control antibody. Mice were assessed by CT/SPECT at
24, 48, and 72 hours post–transfer. Immediately before
transfer, 25% of donor T cells expressed MCAM as de-
termined by flow cytometric analysis (data not shown).
While no significant diminution of CD4+ cell migration
was seen with the MCAM blocking antibody in the
brain, lymph nodes, spleen, or kidneys, anti-MCAM
Figure 3 MPTP-intoxication increases T cell migration. CD3+ T cells were obtained and enriched from spleen and lymph nodes of male donor
C57BL/6J mice. Isolated T cells were activated with anti-CD3 for 3 days. Syngeneic recipients were treated with 4 doses of MPTP-HCl in PBS (18 mg/kg,
based on freebase MPTP) or PBS alone; each dose administered at 2 hour intervals. Activated T cells were labeled with 111In-oxyquinoline (GE Healthcare),
and 20 ×106 111In-labeled T cells were adoptively transferred to each MPTP- or PBS-treated recipient. CT/SPECT images from each animal were acquired
at 24, 48, 72, 96, and 120 hours post-transfer. For each mouse at each sampling time, electronic bit maps were drawn to circumscribe (A) brain, (B) lungs,
(C) kidneys, (D) spleen, (E) cervical lymph nodes, (F) all other lymph nodes, and entire body. Counts of radiolabeled T cells were determined by digital
image analysis software (VIVID, GE Healthcare) and corrected for decay from the time of labeling. Counts for each organ were normalized as the
percentage of total body counts for each time (A-F). Means ± SEMs of radiolabel percentages were determined for 3–5 mice/treatment group and
differences between the 2 treatment groups were determined by Student’s t-test where p ≤0.05 was considered significant.
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lungs of MPTP mice (Figure 5). These data support the
notion that Th17 Teffs are capable of extravasation and
accumulating in the brains of MPTP mice when ad-
equate numbers of Teffs are transferred. However,
blocking MCAM did not adequately inhibit migration of
donor T cells and may have enhanced accumulation,
suggesting that MCAM may not play an active role in T
cell extravasation within the SN in the MPTP model and
may not play a role in exacerbation of neurodegenera-
tion. The possibilities exist that very few Teffs, below thethreshold of detection, are necessary to affect neuro-
degeneration or that Teffs can function at a distance in
an endocrine or paracrine fashion without entering the
brain parenchyma.
Blocking MCAM provides partial neuroprotection in vivo
To assess the role of MCAM in MPTP-induced neuro-
degeneration, the extent of Teff-mediated exacerbation
of dopaminergic neuronal loss was measured in MPTP-
treated mice. For these studies, N-4YSyn-specific Teffs
were adoptively transferred to MPTP-treated recipient
Figure 4 Expression of MCAM (CD146) parallels MPTP
treatment and adoptive T cell transfers. CD3+ T cells were
obtained from donor mice expressing CD90.1 (Thy1.1) and were
activated with anti-CD3. (A) Following activation, and prior to adoptive
transfer (AT), donor cells were analyzed for co-expression of CD4 and
CD146 (CD4+CD146+) (Pre AT). Activated donor T cells (Thy1.1) were
adoptively transferred to recipient mice expressing CD90.2 (Thy1.2)
after treatment with MPTP at dosages of 18 mg/kg every 2 hours for
4 doses or with PBS. Thus, detection of Thy1.1 or Thy1.2 by flow
cytometric analysis differentiates donor (adoptively transferred) and
recipient (endogenous) T cells, respectively. (A) Forty-eight hours
after adoptive transfer (AT), spleens (SP) and lymph nodes (LN) were
removed from recipient animals and cells were analyzed by flow
cytometric analysis for percentages of CD4+CD146+ T cells among
donor (Thy1.1) T cells. (B) Twenty-four or forty-eight hours after PBS- or
MPTP-treatment, lymph nodes were removed from mice that did not
receive adoptive transfer, and cells analyzed by flow cytometric analysis
for percentages of CD4+CD146+ T cells among the endogenous
Thy1.2+ T cells. Additionally, 48 hours after adoptive transfer, lymph
nodes from recipient mice were removed and analyzed for percentages
of CD4+CD146+ T cells among the endogenous recipient Thy1.2 T cells.
Means ± SEMs were determined from data within the 95% confidence
intervals of the means for n =4-5 mice per group and were compared
by one-way ANOVA with Fisher’s LSD post-hoc test where p ≤0.05 was
considered significant.
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isotype control antibody, or fingolimod, a sphingosine-1
phosphate inhibitor that is known to sequester T cells
within secondary lymphoid organs [157-160]. Seven days
post-MPTP treatment, brains were removed, sections of
midbrain stained for tyrosine hydroxylase (TH) expres-
sion, and surviving dopaminergic neurons determined
by stereological analysis. Numbers of TH immunoreac-
tive (TH+) neurons in SN from recipient mice treated
with MPTP, Teffs, and anti-MCAM were slightly ele-
vated, although not significantly (p = 0.06) compared to
those treated with MPTP and Teffs that received either
isotype control antibody or no other treatment (Figure 6).
This suggested that MCAM may not play a critical role
in Teff-mediated exacerbation of dopaminergic neuro-
degeneration, but rather may have a minor effect on
neurodegenerative processes if blocked. Interestingly,
numbers of TH+ neurons from animals treated with
MPTP, Teffs, and fingolimod were significantly diminished
compared to those similarly treated recipients that receive
anti-MCAM. This indicated that blockage of sphingosine-
1-phosphate receptor and sequestration of T cells signifi-
cantly increased the neurodegenerative processes. This
may be due to the inability of fingolimod to sequester
effector memory T cells from circulation [159-161] or that
Tregs may be preferentially sequestered in lymphoid
tissues with loss of their neuroprotective capability in the
brain [162]. Moreover, these data do not rule out the
possibility that Teffs in the MPTP model may function
outside the brain parenchyma.
Conclusions
Considerable evidence supports the notion that T cell-
mediated immunity plays an important role in disease
progression in neurodegenerative disorders. This is most
evident in MS with increased activity of autoreactive Teffs
for self-antigens that comprise the myelin sheath. MS
seems to be the most extreme disorder whereby unre-
gulated T cell immunity, for the most part, mediates direct
neurotoxicity as well as drives other components of the
immune system to produce autoantibodies (B cells) and
neuroinflammation (reactive microglia and infiltrating
macrophages). Expectedly in MS, Treg levels and function
are most notably found to be diminished compared to the
unaffected populations. In ALS, numerous alterations in
adaptive immunity are also well-known, and range from
increased levels of anti- self-antibodies to diminished Treg
levels and increased levels of proinflammatory Teffs not
only in the peripheral blood, but also in sites of neurode-
generation within the spinal cords of ALS patients. More-
over, increased expression of MHC II by APCs and
microglia/macrophages suggests the association of a sys-
temically activated immune system in ALS. AD patients
also exhibit significant aberrations in immune cells and
Figure 5 Anti-MCAM treatment affects T cell migration to the lungs but not brain. Donor CD4+ cells were isolated from spleens and lymph
nodes of C57BL/6 male mice. T cells were activated and polarized by culture for 5 days in the presence of anti-CD3 and a Th17-polarizing cocktail
(3 ng/ml TGF-β, 10 ng/ml IL-6, 5 ng/ml IL-1β, 10 ng/ml IL-23, 3 μg/ml anti IL-4, 3 μg/ml anti IL-12, 3 μg/ml anti IFN-ɣ, and 3 μg/ml anti IL-2). Th17 Teffs
were harvested and labeled with 111In-oxyquinoline and 20 × 106 111In-labeled Th17 Teffs were adoptively transferred to recipients treated with MPTP
at dosages of 18 mg/kg every 2 hours for 4 doses. One hour prior to adoptive transfer and every 24 hours thereafter, recipients were treated ip with
10 mg/kg of either anti-MCAM or rat isotype control antibody. CT/SPECT images of each animal were acquired at 24, 48, and 72 hours post-transfer.
Within tomographic images, electronic bit maps were drawn to circumscribe regions of interest that encompassed (A) brain, (B) lungs, (C) kidneys,
(D) spleen, (E) cervical lymph nodes, (F) remaining lymph nodes, and included the entire body. Counts of radiolabeled T cells for each organ and
entire body were determined by digital image analysis software (VIVID, GE Healthcare) and corrected for decay from the time of labeling. Counts for
each organ were normalized as the percentage of total body counts at each time (A-F). Means ± SEMs of radiolabel percentages were determined for
3–4 mice/treatment group and differences of percentages between isotype antibody and anti-MCAM treatment groups were determined by Student’s
t-test where p ≤0.05 was considered significant.
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associated with increased neuroinflammation that drives
disease progression. While wide variability in levels of im-
mune cells is exhibited among studies of AD patients,
CD4+ T cells are chiefly reported to be in fluctuation with
opposing pro-inflammatory Teffs and anti-inflammatory
T cells or T cell functions at imbalance. The recent clinical
trial of an Aβ1-42 experimental vaccine in AD patientswhich drove immune responses of some patients toward a
T cell-mediated meningoencephalitis underscores the pu-
tative precipice by which this imbalance hangs and awaits
only the slight nudge of the T cell response to drive dis-
ease progression toward either neurotoxicity or neuropro-
tection. In PD, loss of dopaminergic neurons is also
associated with a neuroinflammatory component, which is
thought to play a key role in disease progression. Recent
Figure 6 Blocking MCAM following N-4YSyn-specific splenocyte
transfers elicits partial neuroprotection. Donor immune cells
containing N-4YSyn-specific Teffs were obtained from spleens of
mice immunized and boosted with N-4YSyn. To recipient mice that
were treated with MPTP at dosages of 18 mg/kg every 2 hours for 4
doses, 30 × 106 donor cells were adoptively transferred (AT) twelve
hours after the last dose of MPTP, while one group of MPTP mice
received no donor immune cells. Of the 4 groups that received
donor immune cells, one group received no other treatment, one
group was treated with 10 mg/kg rat isotype control antibody
(MPTP/Isotype/AT), one group with 10 mg/kg anti-MCAM antibody
(MPTP/anti-MCAM/AT), and one group with 1 mg/kg fingolimod
(MPTP/fingolimod/AT). Antibody and fingolimod treatments began
the day before adoptive transfer and continued until the end of study.
One group was treated with only PBS (PBS), and served as total neuron
control. Seven days after MPTP treatment, mice were terminally
anesthetized, transcardially perfused with PBS for exsanguination, fixed
with 4% paraformaldehyde in PBS, and brains removed and processed
for immunohistochemistry. Brains were sectioned through the
midbrain, immunostained with rabbit anti-tyrosine hydroxylase (TH)
and HRP-conjugated goat anti rabbit IgG, and visualized with DAB.
Total numbers of surviving dopaminergic neurons (TH+) in the SN
were quantified by stereological analysis (Stereo Investigator, MBF
Bioscience). Means ± SEMs of total numbers of surviving dopaminergic
neurons were determined from 5–8 mice per treatment group and
were compared by one way ANOVA and Fisher’s LSD post-hoc test.
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T cells with effector/memory phenotypes as well as cor-
responding diminution of Treg function, both correlating
with the severity of motor dysfunction. Taken together,
the preponderance of evidence supports a role for adap-
tive immune responses in neurodegenerative disorders,
particularly those associated with a neuroinflammatory
component. However, the mechanism(s) utilized and the
epitopes recognized have yet to be determined for each of
these disorders. One perspective is that with low regula-
tory function, peripheral Teffs, which are normally kept in
check, can expand and evade control to exacerbate diseaseprocesses and accelerate or amplify disease progression. In
different proteinopathies, the possibility exists that the
modified, misfolded, and aggregated proteins associated
with each particular disorder (MBP, MOG, SOD1, Aβ, tau,
or α-syn) are not adequately degraded or eliminated, and
eventually drain with inflammatory mediators to peripheral
lymphoid tissues, wherein they are preferentially processed
and presented by APCs. Proinflammatory environments in
the draining tissues with increased presentation of modi-
fied self-proteins could provide conditions more condu-
cive to elicitation of Teffs such as Th1 and Th17 cells.
Marshaling those Teffs to sites of neuroinflammation, and
evoking their destruction potential would provide added
neurotoxic conditions. Conversely, mobilizing anti-inflam-
matory T cells, such as Th2 and Tregs, to these same sites
may provide neuroprotective responses and serve as
therapeutic strategies to control the proinflammatory pro-
cesses of neurodegeneration. Thus, the mechanism(s) of
T cell migration and extravasation to sites of neuroinflam-
mation remain major issues in neurodegenerative disor-
ders. Indeed, with the exception of MS whereby treatment
with fingolimod or natalizumab limits T cell migration
and extravasation, the necessity of Teff infiltration for ex-
acerbation of neurotoxicity in other neurodegenerative
disorders has not been established.
The lack of significant neuroprotection afforded with
the administration of anti-MCAM described herein could
be due to a number of factors. First, administration of the
MCAM blocking antibody may have been needed at times
other than 1 hour prior to adoptive transfer or at a greater
concentration to ensure that the antibody had sufficient
opportunities to bind to the MCAM receptor. Second, the
relatively low percentage of adoptively transferred cells
that expressed MCAM prior to adoptive transfer could
have proven problematic since the antibody could not
have been able to find its target within the entire circula-
tion. Third, the use of N-4YSyn as stimulation instead of
anti-CD3 may not have activated the cells enough to in-
crease infiltration into the CNS. The amount of N-4YSyn
specific cells that were transferred into MPTP-intoxicated
MPTP mice may have been an insufficient number to see
increased migration leading to a lack of significant differ-
ences between MPTP and PBS treated mice as well.
Lastly, T cell extravasation from the circulation does not
rely on one CAM alone, but rather is a combination of
CAMs that work in a redundant and synergistic fashion to
allow cells to cross endothelial cell barriers. This leads to
the possibility that blocking MCAM only is not sufficient
to halt T cell infiltration as other CAMs could take over
the role of MCAM. If complete and significant blockage
of CD4+ cell entry to the CNS is the ultimate goal, ad-
ministration of a variety of CAM blocking agents may
be necessary to target multiple steps in immune cell
extravasation.
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Additional file 1: CT/SPECT imaging of migration and accumulation
of 111In-labeled Teffs in PBS-treated mice. CD3+ T cells were harvested
and enriched from spleens and lymph nodes of C57BL/6 donor mice.
Isolated cells were activated using anti-CD3 for 3 days. Recipient mice were
treated with 4 doses of PBS; one dose every 2 hours. Twelve hours after the
last injection, activated Teffs were labeled with 111In-oxyquinoline and 20 × 106
labeled cells were adoptively transferred into PBS-treated recipient
mice. CT/SPECT images were acquired at 24 hours after transfer.
Additional file 2: CT/SPECT imaging of migration and accumulation
of 111In-labeled Teffs in MPTP-treated mice. CD3+ T cells were
harvested and enriched from spleens and lymph nodes of C57BL/6
donor mice. For 3 days, isolated cells were activated using anti-CD3.
Recipient mice were treated with 4 doses, one dose every 2 hours, of
MPTP at 18 mg/kg. Twelve hours post MPTP injection, activated Teffs
were labeled with 111In-oxyquinoline and 20 × 106 labeled cells were
adoptively transferred into MPTP-treated recipient mice. CT/SPECT images
were acquired at 24 hours after transfer.
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